Safety Reactogenicity and Immunogenicity Study of ReCOV

  • End date
    Jul 1, 2022
  • participants needed
  • sponsor
    Jiangsu Rec-Biotechnology Co., Ltd.
Updated on 1 September 2021


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen that causes a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19), which is spreading all over the world. This virus can cause acute respiratory distress syndrome (ARDS) with a high fatality rate.

In this phase I first-in-human clinical trial, healthy volunteers in two different age cohorts and two dose cohorts will be vaccinated twice with the candidate vaccine ReCOV.

The aim of the study is to assess the safety and reactogenicity of the candidate vaccine and to characterize its immunogenicity.


A total of 100 participants will receive the following vaccine regime:

First, 20 young adult participants (18 to 55 years old) will receive 20g of ReCOV vaccine on days 0 and 21.

Then, 20 young adult participants (18 to 55 years old) will receive 40g of ReCOV vaccine on days 0 and 21, and 20 old adult participants (56 to 80 years old) will receive 20g of ReCOV vaccine on days 0 and 21.

Finally, 20 old adult participants (56 to 80 years old) will receive 40g of ReCOV vaccine on days 0 and 21.

In the same time, 8 participants for each cohort, total 32 participants will receive 0.5ml of normal saline on days 0 and 21.

Safety and immunogenicity data will be collected throughout the study, which concludes at 12 month after the second dose.

Condition COVID19
Treatment Placebo, Recombinant two-component COVID-19 vaccine (CHO cell)
Clinical Study IdentifierNCT04818801
SponsorJiangsu Rec-Biotechnology Co., Ltd.
Last Modified on1 September 2021


Yes No Not Sure

Inclusion Criteria

Subjects are eligible to be included in the study only if ALL of the following
criteria apply at any time starting from Screening up to Day 1 prior to IP
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol
Male or female subjects who are 18 years old at the time of Screening (signing the ICF)
For the younger adult group: 18 to 55 years, inclusive
For the older adult group: 56 to <80 years
Have a body mass index (BMI) between 18.5 and 35.0 kg/m2
Subjects who are of general good health according to the Investigator's assessment, based on a complete medical history without major pathology, and as determined by medical evaluation (including physical examination, electrocardiogram (ECG), vital signs, and clinical laboratory tests). Subjects in the older adult population who have medically stable, well-controlled comorbidities may be enrolled at the discretion of the Investigator
NOTE: All clinical laboratory values should be within reference ranges unless
confirmed by Investigator or delegate as not clinically significant. One
repeat evaluation of ECG, vital signs, and clinical laboratory tests will be
permitted, at the discretion of the Investigator
\. Subjects who test negative for hepatitis B surface antigen (HBsAg)
hepatitis B core antibodies (anti-HBc), anti-hepatitis C virus (HCV)
antibodies, and anti-human immunodeficiency virus (HIV) 1 and 2 antibodies at
\. Subjects who test negative for SARS-Cov-2 infection, based on a reverse
transcriptase polymerase chain reaction (RT-PCR) test and serological test for
SARS-COV-2 IgM and/or IgG antibodies at Screening
\. Female subjects are eligible to participate if not pregnant, not
breastfeeding, and at least 1 of the following conditions applies
Is not a woman of childbearing potential (WOCBP), defined as
Surgically sterile (documented hysterectomy, bilateral salpingectomy, or
bilateral oophorectomy, as confirmed by review of the subject's medical
records, medical examination, or medical history interview), or Postmenopausal
(defined as no menses for 12 months without an alternative medical cause. A
high follicle-stimulating hormone [FSH] level in the postmenopausal range may
be used to confirm a postmenopausal state in women not using hormonal
contraception or hormonal replacement therapy [HRT]. However, in the absence
of 12 months of amenorrhea, a single FSH measurement is insufficient). Female
subjects on HRT and whose menopausal status is in doubt will be required to
use 1 of the non estrogen hormonal highly effective contraception methods from
Day 1 until at least 6 months after the second dose of IP if they wish to
continue their HRT during the study. Otherwise, they must discontinue HRT to
allow confirmation of postmenopausal status before study enrollment
\. Is a WOCBP who agrees to use a highly effective method of contraception
consistently and correctly from Day 1 until at least 6 months after the second
dose of IP
\. Nonsterilized male subjects with female partners of childbearing potential
are eligible to participate if they agree to ONE of the following from Day 1
until at least 6 months after the second dose of IP and refrain from donating
sperm during this
Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent
Agree to use a male condom and have their partner use of a contraceptive method with a failure rate of <1% per year when having penile-vaginal intercourse with a WOCBP who is not currently pregnant
Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration

Exclusion Criteria

Subjects are excluded from the study if ANY of the following criteria apply at any time starting from Screening up to Day 1 prior to IP administration
History of clinically significant and uncontrolled hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic disease in the opinion of the Investigator within 12 months prior to Screening
Individuals with behavioral or cognitive impairment in the opinion of the Investigator
Individuals with any progressive or severe neurologic disorder, seizure disorder, or history of Guillain-Barr syndrome
Individuals with known or suspected impairment of the immune system, such as
Use of systemic (oral or parenteral) corticosteroids for 14 consecutive days within 60 days prior to Day 1. Use of inhaled, intranasal, or topical corticosteroids is allowed. NOTE: Systemic (oral or parenteral) corticosteroids are also prohibited for 3 weeks after the second dose of the IP
Receipt of cancer chemotherapy within 5 years prior to Day 1
Receipt of immunostimulants or immunosuppressants within 60 days prior to Day 1
Known HIV or acquired immune deficiency syndrome
Subjects with active or prior documented autoimmune disorder (such as potential immune mediated diseases [pIMDs])
Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Day 1 or planned during the full length of the study
Being treated for tuberculosis
History of allergic disease or reactions associated with previous vaccinations or likely to be exacerbated by any component of the IP
Individuals who have had a previous confirmed or suspected illness caused by SARS-CoV-1, SARS-CoV-2, or MERS-CoV
Individuals who have had a malignancy (excluding nonmelanotic skin cancer) or lymphoproliferative disorder within the past 5 years from the first dose of the IP (Day 1)
History of urticaria within 1 year prior to Screening
History of hereditary angioneurotic edema or acquired angioneurotic edema
History of asplenia or functional asplenia
History of platelet disorder or other bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the Investigator, contraindicate intramuscular injection
Current febrile illness or body temperature 38.0C or other moderate to severe illness within 24 hours of IP administration on Day 1. This condition is considered to be temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met
Any current active infections, including localized infections, or any recent history (within 1 week prior to IP administration) of active infections or cough; or a history of recurrent or chronic infections (>3 infections/year)
Individuals with a history of drug or alcohol abuse (with an average intake exceeding 10 drinks/week for women and 15 drinks/week for men: 1 drink = 360 mL of beer, 150 mL of wine, or 45 mL of spirits) or drug addiction (including soft drugs like cannabis products) within the past 2 years
Current heavy smoker, defined as smoking 20 cigarettes/day (1 pack or equivalent), or a former heavy smoker who was an active smoker within the past 1 year prior to Screening
Individuals who faint at the sight of blood or needles
Participation in another interventional clinical study (including a bioequivalence study) with an investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of the IP
Individuals who have received any prior investigational or approved vaccine against a coronavirus, including but not limited to SARS-CoV-1, SARS-CoV-2, and MERS-CoV
Individuals who have received any other licensed vaccines within 14 days (for inactivated vaccines) or 30 days (for live or attenuated vaccines) prior to enrollment in this study, or those who are planning to receive any vaccine within 30 days before the first dose of IP or during the study, with the exception of the seasonal influenza vaccine
Individuals must not have donated blood for 30 days prior to Day 1 and must agree to not donate blood for 6 months after Day 1 (receipt of first dose of the IP)
Individuals with any condition that, in the opinion of the Investigator, would interfere with the study objectives or pose additional subject risk
Any persons who are
An employee of the study site, Investigator, contract research organization (CRO) or Sponsor
A first-degree relative of an employee of the study site, the Investigator, CRO, or the Sponsor
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note